Good morning,
my name is Nicholas Di Prospero
and I am a clinical fellow with
Kurt Fischbeck. Through my time
with him, I've been studying
mostly Huntington's Disease in a
model system, which we're hoping
share some features of the
pathology with Kennedy's, in hopes
of designing therapeutic
interventions. And, we're also
spending time evaluating the
possibilities of doing some
clinical trials at NIH for
Kennedy's Disease in the future.
So, Dr.
Fischbeck, Dr. Sumner, and myself
have talked at some length about
doing a clinical trial here in the
United States for Kennedy's
Disease, and in preparation for
that, we're working on designing a
survey, similar to one that the
Kennedy's Disease Association has
already put out. I was trying to
get a good idea about the clinical
issues, along with other features
that are shared that may not be
completely recognized in the
current literature regarding
Kennedy's Disease.
In that sense,
when you design a clinical trial,
you want to actually cast a very
wide net so that we can not just
look at things that we can measure
objectively such as muscle testing
and nerve conduction, but things
that are also subjectively
important to a patient's quality
of life standards. When you
actually go to look at the effects
of a drug, some things may change
disproportionately in terms of
time, so you may notice that you
may have a better quality of life
in terms of being able to button
your shirt before you're able to
life ten pounds more with your
leg. So, we're trying to cast a
broad net when we do the clinical
trial in the hopes of gaining a
lot more information. Therefore,
we're trying to bring out, or
develop as I said, a survey form,
which we're hoping we can get out
sometime in the next few months.
Additionally,
we'll keep in very close contact
with Dr. Sobue's group, in
following their trial to see how
they're making out in terms of
progress and discuss the possible
therapeutic modalities in terms of
drugs that we'd like to pursue.
Hopefully Dr. Sobue will be able
to, give you a little better
information about how his work's
progressing as well. (Applause)
Question from
Audience:
(Inaudible).
We've had (inaudible) people to
our survey and we are all
volunteer. It's a tedious thing to
get this information collated.
We are not finished with it with
but there's a wealth of critical
information there, but frankly
(inaudible) we'll need help. Is
there a way that, through NIH or
through some funding group, that
we could get funded, if you will,
and we could hire somebody to do
some of the things that we need to
do to assist you.
Di Prospero
Funding
issues are difficult ones. Most
funding comes from grant sources,
but what you're, what you're
describing is really my day job.
My day job is involved in trying
to pursue really the essence of
what you are doing here. So the
idea of, of not just getting
information but analyzing it and
collating it, as you're saying, is
something that, individual
researchers can do. As far as
doing it yourself, I don't
necessarily know about how you
could go about getting grant money
from something like the NIH. What
it essentially comes down to is
that researchers like ourselves,
myself, or others basically apply
for additional funds saying that
this is part of their objectives
in their research design that they
want to look at. So what is great
is that taking some of the
observations from the small survey
that's been done here analyzing
the data and refining it. I know
that there's been a number of, of
respondents to the KDA website.
Hopefully we can cast a very large
net and be able to solicit
information from even more people.
But again I think, it falls really
to the research personnel to
really kind of pursue what you're
asking.
Question:
We just
don't have the time to do this. In
the interest of time and sharing
(inaudible) would that be of
benefit?
Di Prospero:
Sharing information is wonderful.
However, to do anything under the
auspices of a clinical trial,
we're asked to go through
standards to provide patient
protection, which is done through
what's called the Institution
Regulatory Board, or Review Board,
in other words an IRB. This review
process was instituted by federal
law for protection of patients and
individual subjects. So basically
sharing some information with us
in an anonymous fashion is well
and good, but for us to actually
go about and communicate that
information in a publication or
something to the worldwide
community of scientists, has to be
done under certain stringent
guidelines. So, we have to
actually go through many processes
in order to bring forth a kind of
survey, but having a starting
point from the information you
gathered is a great boon.
Audience:
Nick and I
were just talking about that at
the break that our survey is
almost complete as far as just
getting information tallied. We're
not extrapolating any correlations
or trying to make any judgments at
this time, but just to get the raw
data over to them and then he can
look through our survey, he said
he may even be able to utilize
portions of it in his own survey;
he's got to develop it towards
their clinical trial, in the way
that (inaudible).
Question:
When your
survey is developed who will be
asked to complete?
Di Prospero:
Basically,
anyone who has confirmed Kennedy's
disease and is willing to
participate. The great thing is
the KDA is a wonderful resource
for patients and researchers. The
KDA may advertise the fact that we
are doing this study on their
website and we would also solicit
through the NIH sponsored
advertisements and website
basically saying we have developed
this survey to help us get a
better understanding of Kennedy's
disease. It is then up individuals
to contact us and express an
interest. The procedure, would be
to present further information and
provide the patients with a
consent form that one would sign
indicating that he agrees to be
part of this survey. In this way,
a formal consent should explain
the study so everybody fully
understands what's involved.